ASH Annual Meeting and Exposition | Conference

Lenalidomide/Rituximab PFS Benefit Maintained in Elderly Subgroup With Indolent Non-Hodgkin Lymphoma

December 9th 2019

The combination of lenalidomide (Revlimid) and rituximab showed a 34% reduction in the risk of disease progression or death compared with rituximab plus placebo in patients ≥70 years old with indolent non-Hodgkin lymphoma, although it was not found to be statistically significant.

Ibrutinib May Thwart PFS Decline in R/R Mantle Cell Lymphoma

December 9th 2019

In patients with relapsed mantle cell lymphoma, treatment with ibrutinib might mitigate a historical trend toward decreased progression-free survival with succeeding lines of therapy.

Liso-Cel Induces High Rate of Durable Responses in LBCL

December 9th 2019

CD19-directed CAR T-cell therapy induced a high rate of rapid and durable complete responses in patients with aggressive relapsed/refractory large B-cell lymphoma.

Novel Triplet Shows Early Promise for Pretreated CLL

December 8th 2019

The triplet of umbralisib, ublituximab, and venetoclax induced a complete remission rate of 44% as a treatment for patients with relapsed/refractory chronic lymphocytic leukemia.

Triplet Regimen Induces High Rate of CR in R/R Follicular Lymphoma

December 8th 2019

The combination of polatuzumab-vedotin (Polivy), obinutuzumab (Gazyva), and lenalidomide (Revlimid) induced a high rate of durable responses in patients with relapsed/refractory follicular lymphoma.

Dr. Tam on Results of the CAPTIVATE Trial in CLL

December 8th 2019

Constantine S. Tam, MD, MBBS, associate professor, Peter MacCallum Cancer Centre, discusses the results of the phase II CAPTIVATE study in chronic lymphocytic leukemia (CLL).

Dr. Biran on 2-Year Update of Immunotherapy Triplet in High-Risk Multiple Myeloma

December 8th 2019

Noa Biran, MD, physician, John Theurer Cancer Center, discusses the 2-year update of a phase II trial of pembrolizumab (Keytruda), lenalidomide (Revlimid), and dexamethasone as post-autologous stem cell transplant consolidation in patients with high-risk multiple myeloma.

Acalabrutinib Triplet Highly Active in Frontline CLL

December 8th 2019

The triplet of acalabrutinib (Calquence), venetoclax (Venclexta), and obinutuzumab (Gazyva; AVO) is highly active as frontline therapy for patients with chronic lymphocytic leukemia.

Ibrutinib/Rituximab Combo Retains PFS Advantage Over FCR in CLL

December 8th 2019

With extended follow-up, progression-free survival continues to be superior with the combination of ibrutinib and rituximab compared with fludarabine, cyclophosphamide, and rituximab for patients ≤70 years with previously untreated chronic lymphocytic leukemia.

Frontline Ibrutinib/Venetoclax Combo Leads to High Rates of Undetectable MRD in CLL

December 8th 2019

The first-line combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) led to a 75% undetectable minimal residual disease rate in peripheral blood and 72% in bone marrow in patients with chronic lymphocytic leukemia.

Axi-Cel Elicits 47% 3-Year OS Rate in B-Cell Lymphoma

December 8th 2019

The CAR T-cell therapy axicabtagene ciloleucel (axi-cel; Yescarta) induced a median overall survival of 25.8 months for patients with refractory large B-cell lymphoma.

Anti-BCMA CAR-T JNJ-4528 Hits 100% Response Rate in Heavily Pretreated Myeloma

December 8th 2019

The BCMA-directed CAR T-cell therapy JNJ-4528 achieved a 100% overall response rate with early and deep responses in 29 patients with heavily pretreated relapsed/refractory myeloma.

Novel Antibody Elicits Complete Remissions in NHL After CAR Relapses

December 8th 2019

Mosunetuzumab, a novel bispecific antibody, generated durable responses in patients with highly refractory non-Hodgkin lymphomas, including complete remissions in 22.2% of those who had previously received chimeric antigen receptor T-cell therapy.

Extramedullary Multiple Myeloma Responds to Dual-Targeting CAR T-Cell Therapy

December 7th 2019

Chimeric antigen receptor T-cell therapy targeting both BCMA and CD38 induced an objective response in >90% of patients with multiple myeloma who had been treated with at least 3 prior therapies and whose disease had spread outside of the bone marrow.

Acalabrutinib Alone or in Combination Improves PFS in Frontline CLL

December 7th 2019

Acalabrutinib (Calquence) as a single agent or in combination with obinutuzumab (Gazyva) significantly improved progression-free survival compared with obinutuzumab plus chlorambucil in treatment-naïve patients with chronic lymphocytic leukemia.

Anti-BCMA, CD3 Agent CC-93269 Shows Promise for Heavily Pretreated Myeloma

December 7th 2019

CC-93269 showed encouraging signs of dose-dependent efficacy with a safety profile that continues to be refined for patients with heavily pretreated relapsed/refractory multiple myeloma.

Fate Touts Novel Off-the-Shelf Cell Therapy

December 7th 2019

An investigational new drug application for the therapy, which is labeled FT596, was approved in September 2019 and human trials are scheduled to begin in the first quarter of 2020.

Landgren Previews Pivotal ASH 2019 Myeloma Data

December 6th 2019

Ahead of the 2019 ASH Annual Meeting, C. Ola Landgren, MD, PhD, shares insight on the potentially practice-changing data in the multiple myeloma paradigm that will be discussed at the conference.

Dr. Patel on Induction Therapy With Bendamustine and Rituximab in MCL

December 11th 2018

Krish Patel, MD, oncologist, Swedish Cancer Institute, discusses induction therapy with bendamustine and rituximab (Rituxan; BR) in the treatment of patients with mantle cell lymphoma (MCL).

Dr. Gauthier on Potential for CAR T Cells in CLL

December 11th 2018

Jordan Gauthier, MD, MSc, senior clinical research fellow, Fred Hutchinson Cancer Research Center, discusses the potential for chimeric antigen receptor T-cell therapy in the treatment of chronic lymphocytic leukemia.